These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15905735)

  • 1. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.
    Mirochnick M; Stek A; Acevedo M; Keller M; Holland D; Capparelli E; Connor J; Huang S; Hughes M; Watts H; Mofenson L; Bryson Y
    J Acquir Immune Defic Syndr; 2005 Jun; 39(2):189-94. PubMed ID: 15905735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
    Bryson YJ; Mirochnick M; Stek A; Mofenson LM; Connor J; Capparelli E; Watts DH; Huang S; Hughes MD; Kaiser K; Purdue L; Asfaw Y; Keller M; Smith E;
    HIV Clin Trials; 2008; 9(2):115-25. PubMed ID: 18474496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.
    Bennetto-Hood C; Bryson YJ; Stek A; King JR; Mirochnick M; Acosta EP
    HIV Clin Trials; 2009; 10(1):41-7. PubMed ID: 19362995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.
    Mirochnick M; Nielsen-Saines K; Pilotto JH; Pinto J; Veloso VG; Rossi S; Moye J; Bryson Y; Mofenson L; Camarca M; Watts DH;
    Pediatr Infect Dis J; 2011 Sep; 30(9):769-72. PubMed ID: 21666540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
    Litalien C; Faye A; Compagnucci A; Giaquinto C; Harper L; Gibb DM; Jacqz-Aigrain E;
    Pediatr Infect Dis J; 2003 Jan; 22(1):48-55. PubMed ID: 12544409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum.
    Eke AC; McCormack SA; Best BM; Stek AM; Wang J; Kreitchmann R; Shapiro D; Smith E; Mofenson LM; Capparelli EV; Mirochnick M;
    J Clin Pharmacol; 2019 Mar; 59(3):386-393. PubMed ID: 30358179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
    Hirt D; Urien S; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Treluyer JM
    Br J Clin Pharmacol; 2007 Nov; 64(5):634-44. PubMed ID: 17892516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.
    Read JS; Best BM; Stek AM; Hu C; Capparelli EV; Holland DT; Burchett SK; Smith ME; Sheeran EC; Shearer WT; Febo I; Mirochnick M
    HIV Med; 2008 Nov; 9(10):875-82. PubMed ID: 18795962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
    Khaliq Y; Gallicano K; Seguin I; Fyke K; Carignan G; Bulman D; Badley A; Cameron DW
    Br J Clin Pharmacol; 2000 Aug; 50(2):108-15. PubMed ID: 10930962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
    van Heeswijk RP; Khaliq Y; Gallicano KD; Bourbeau M; Seguin I; Phillips EJ; Cameron DW
    Clin Pharmacol Ther; 2004 Dec; 76(6):588-97. PubMed ID: 15592330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
    Payen S; Faye A; Compagnucci A; Giaquinto C; Gibbs D; Gomeni R; Bressolle F; Jacqz-Aigrain E
    Antimicrob Agents Chemother; 2005 Feb; 49(2):525-35. PubMed ID: 15673728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
    Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum.
    Fang A; Valluri SR; O'Sullivan MJ; Maupin R; Jones T; Delke I; Clax P
    HIV Clin Trials; 2012; 13(1):46-59. PubMed ID: 22306587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.
    Acosta EP; Zorrilla C; Van Dyke R; Bardeguez A; Smith E; Hughes M; Huang S; Pitt J; Watts H; Mofenson L;
    HIV Clin Trials; 2001; 2(6):460-5. PubMed ID: 11742433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
    Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
    Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
    Boffito M; Pozniak A; Kearney BP; Higgs C; Mathias A; Zhong L; Shah J
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4386-9. PubMed ID: 16189129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.